{"id":849,"date":"2026-10-19T21:12:40","date_gmt":"2026-10-20T01:12:40","guid":{"rendered":"http:\/\/novameds.local\/ca\/?post_type=product&#038;p=849"},"modified":"2026-10-19T21:58:28","modified_gmt":"2026-10-20T01:58:28","slug":"catalog-trevogrumab-1mg","status":"publish","type":"product","link":"https:\/\/novameds.health\/ca\/product\/catalog-trevogrumab-1mg\/","title":{"rendered":"Trevogrumab 1mg"},"content":{"rendered":"<section id=\"composition\" data-nav=\"Composition and product details\">\n<h2>Composition and product details<\/h2>\n<div class=\"nm-catalog-document\">\n<div>\n<h2>Overview<\/h2>\n<div>\n<p>Trevogrumab (REGN1033, SAR-391786) is a fully human monoclonal antibody engineered for high-affinity, selective neutralisation of myostatin (GDF-8), a TGF-beta superfamily ligand that functions as a primary negative regulator of skeletal muscle mass. Research interest centers on its specificity for myostatin without cross-reactivity to other ActRIIB-binding ligands such as activins or GDF-11.<\/p>\n<p>Research applications include myostatin pathway antagonist research, antibody-based ligand neutralisation studies, and comparative ActRIIB pathway inhibitor pharmacology.<\/p>\n<ul>\n<li> <span><b>High Purity<\/b> \u2013 99% Purity Guaranteed<\/span><\/li>\n<li> Independently Lab Tested<\/li>\n<li> Research Grade Quality<\/li>\n<li> For Laboratory Research Use Only<\/li>\n<\/ul><\/div>\n<div>\n<p><a href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/384585220\" target=\"_blank\" rel=\"noopener noreferrer\">Molecular data on PubChem<\/a><\/p>\n<div>\n<div><span>Trevogrumab 1mg<\/span><span>1 vial | KIT (10 vials)<\/span><\/div>\n<\/div><\/div>\n<\/p><\/div>\n<div>\n<h2>Properties<\/h2>\n<div class=\"nm-catalog-table\" tabindex=\"0\" role=\"region\" aria-label=\"Product data\">\n<table>\n<tbody>\n<tr>\n<th>Chemical Formula<\/th>\n<td>C6374H9884N1696O2018S46<\/td>\n<\/tr>\n<tr>\n<th>Synonyms<\/th>\n<td>REGN-1033 (REGN1033), Anti-GDF8\/Myostatin antibody, SAR-391786<\/td>\n<\/tr>\n<tr>\n<th>CAS Number<\/th>\n<td>1429201-24-0<\/td>\n<\/tr>\n<tr>\n<th>PubChem CID<\/th>\n<td>384585220<\/td>\n<\/tr>\n<tr>\n<th>Available formats<\/th>\n<td>1 vial \u00b7 KIT (10 vials)<\/td>\n<\/tr>\n<tr>\n<th>Shelf Life<\/th>\n<td>36 months<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div><\/div>\n<div>\n<h2>Research<\/h2>\n<p>\t\t\t\t\t<span>Trevogrumab is a monoclonal antibody studied for its high-affinity, selective binding to myostatin (GDF-8), neutralising its capacity to engage the activin receptor type IIB (ActRIIB) and downstream Smad2\/3 signalling cascade that suppresses skeletal muscle hypertrophy pathways. Its specificity profile distinguishes it from broader-spectrum ActRIIB ligand traps (such as soluble ActRIIB-Fc fusion proteins), which neutralise myostatin alongside activins, GDF-11, and BMP-9\/10, making trevogrumab a research tool for isolating myostatin-specific pathway contributions without confounding activin or BMP pathway effects. In vitro Smad2\/3 reporter assays and rodent muscle-mass studies are standard experimental approaches for characterising trevogrumab&#8217;s neutralising potency and downstream functional effects. Independently third-party HPLC-tested; COA available per batch.<br \/>\n<\/span>\t\t\t\t\t<\/div>\n<div>\n<h2>FAQ<\/h2>\n<div>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>How does Trevogrumab&#8217;s myostatin selectivity distinguish it from broad-spectrum ActRIIB ligand traps in research?<\/span><\/p>\n<\/summary>\n<div>\n<p>Trevogrumab is engineered as a highly specific anti-myostatin (GDF-8) antibody, binding myostatin directly to prevent its engagement of ActRIIB, with minimal cross-reactivity to other TGF-beta superfamily ligands. This contrasts with soluble ActRIIB-Fc fusion protein ligand traps, which sequester myostatin alongside activins, GDF-11, and BMP-9\/10 indiscriminately.<\/p>\n<p>For research questions requiring isolation of myostatin-specific pathway contributions \u2014 without confounding effects from co-inhibited activin or BMP signalling \u2014 trevogrumab&#8217;s selective mechanism is the appropriate experimental tool.<\/p>\n<\/div>\n<\/details>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>What assay formats are used to confirm Trevogrumab&#8217;s neutralizing potency against myostatin-induced signaling?<\/span><\/p>\n<\/summary>\n<div>\n<p>Cell-based Smad2\/3 reporter assays \u2014 using myoblast cell lines such as C2C12 transfected with a Smad-responsive luciferase construct \u2014 are standard for quantifying trevogrumab&#8217;s capacity to block myostatin-induced Smad2\/3 transcriptional activation in a dose-dependent manner, typically expressed as an IC50 or neutralising dose. Surface plasmon resonance (SPR) or other direct binding-affinity methods are used in parallel to characterise trevogrumab&#8217;s intrinsic binding kinetics (Kd, on\/off rates) to recombinant myostatin independent of the cell-based functional readout.<\/p>\n<\/div>\n<\/details>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>What rodent model endpoints are used to evaluate Trevogrumab&#8217;s functional effects on skeletal muscle mass?<\/span><\/p>\n<\/summary>\n<div>\n<p>Rodent studies investigating myostatin pathway antagonists typically measure lean body mass and individual muscle wet weight (e.g. gastrocnemius, quadriceps) following a defined dosing period, alongside functional measures such as grip strength or treadmill exercise capacity. These studies often include muscle fiber cross-sectional area histology to confirm hypertrophy at the cellular level, and serum myostatin\/antibody pharmacokinetic sampling to correlate systemic drug exposure with the magnitude of the observed muscle-mass phenotype.<\/p>\n<\/div>\n<\/details><\/div>\n<\/p><\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>Trevogrumab (REGN1033, SAR-391786) is a fully human monoclonal antibody engineered for high-affinity, selective neutralisation of myostatin (GDF-8), a TGF-beta superfamily ligand that functions as a primary negative regulator of skeletal muscle mass.<\/p>\n<p>Presentation: Trevogrumab 1mg.<\/p>\n<p>Select the required strength and pack size.<\/p>\n<p class=\"nm-research-disclaimer\">For laboratory research only. Not for human or veterinary use.<\/p>\n<p class=\"nm-catalog-image-note\"><small>Illustrative packaging generated with AI.<\/small><\/p>\n","protected":false},"featured_media":995,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[26],"product_tag":[],"nm_classification":[],"class_list":["post-849","product","type-product","status-publish","has-post-thumbnail","product_cat-recovery-regeneration","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"_links":{"self":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product\/849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/comments?post=849"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/media\/995"}],"wp:attachment":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/media?parent=849"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product_brand?post=849"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product_cat?post=849"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product_tag?post=849"},{"taxonomy":"nm_classification","embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/nm_classification?post=849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}